Harvoni (ledipasvir/sofosbuvir)

Many patients pay $0 through manufacturer patient assistance programs. Contact our pharmacists — we handle all the paperwork.

Harvoni was the first once-daily single-tablet regimen for HCV genotype 1, the most common genotype in the United States. It combines ledipasvir and sofosbuvir, and achieves cure rates of 94–99% in 8–12 weeks depending on patient characteristics.

Our specialty pharmacists assist with the complete insurance prior authorization process, Gilead Sciences patient assistance programs, and provide ongoing adherence support throughout treatment.

• Genotype 1 treatment (most common in US)
• 8–12 week treatment duration
• 94–99% cure rate
• Gilead patient assistance program available